Post-translational modification of galectin-3 and its role in biological function

ACS Symposium Series

Volumn 1115, Issue , 2012, Pages 137-151

  Byrd, James C ^a   Mazurek, Nachman ^a   Bresalier, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; ENZYME ACTIVITY; MOLECULAR BIOLOGY; PHOSPHORYLATION;

BIOLOGIC FUNCTIONS; BIOLOGICAL FUNCTIONS; COLON CANCER CELLS; HUMAN BREAST CANCER CELLS; HUMAN POPULATION; POST-TRANSLATIONAL MODIFICATIONS; PROTEOLYTIC CLEAVAGE; STRUCTURAL MODIFICATIONS;

PROTEINS;

EID: 84905284057     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2012-1115.ch008     Document Type: Conference Paper

References (68)

1. Cooper, D. N. W. Galectinomics: Finding themes in complexity. Biochim. Biophys. Acta 2002, 1572, 209-231.
2. Byrd, J. C.; Bresalier, R. S. Galectin-3 in the Progression and Metastasis of Colorectal Neoplasia. In Galectins; Klyosov, A. A., Witzak, Z. J., Platt, D., Eds.; John Wiley and Sons: Newark, NJ, 2009; pp 221-232.
3. Balan, V.; Nangia-Makker, P.; Jung, Y. S.; Wang, Y.; Raz, A. Galectin-3: A novel substrate for c-Abl kinase. Biochim. Biophys. Acta 2010, 1803, 1198-1205.
4. Balan, V.; Nangia-Makker, P.; Kho, D. H.; Wang, Y.; Raz, A. Tyrosinephosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J. Biol. Chem. 2012, 287, 5192-5198.
5. Huflejt, M. E.; Turck, C. W.; Lindstedt, R.; Barondes, S. H.; Leffler, H. L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. J. Biol. Chem. 1993, 268, 26712-26718.
6. Li, X.; Ma, Q.; Wang, J.; Liu, X.; Yang, Y.; Zhao, H.; Wang, Y.; Jin, Y.; Zeng, J.; Li, J.; Song, L.; Li, X.; Li, P.; Qian, X.; Cao, C. c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein galectin- 3. Cell Death Differ. 2010, 17, 1277-1287.
7. Mazurek, N.; Conklin, J; Byrd, J. C.; Raz, A.; Bresalier, R. S. Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. J. Biol. Chem. 2000, 275, 36311-36315.
8. Mazurek, N.; Sun, Y. J.; Liu, K. F.; Gilcrease, M. Z.; Schober, W.; Nangia-Makker, P.; Raz, A.; Bresalier, R. S. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J. Biol. Chem. 2007, 282, 21337-21348.
9. Mazurek, N.; Sun, Y. J.; Price, J.; Ramdas, L.; Schoher, W.; Nangia-Makker, P.; Raz, A.; Bresalier, R. S. Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Res. 2005, 65, 10767-10775.
10. Takenaka, Y.; Fukumori, T.; Yoshii, T.; Oka, N.; Hidenori, I.; Kim, H.-R.; Bresalier, R. S.; Raz, A. Phosphorylation of the N-terminal domain of galectin-3 regulates its cellular localization and anti-apoptotic function in response to chemotherapeutic drugs. Mol. Cell. Biol. 2004, 24, 4395-4406.
11. Yoshi, T.; Fukumori, T.; Honjo, Y.; Inohara, H.; Kim, H. R. C.; Raz, A Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J. Biol. Chem. 2002, 277, 6852-6857.
12. Earl, L. A.; Bi, S.; Baum, L. G. Galectin multimerization and lattice formation is regulated by linker region structure. Glycobiology 2011, 21, 6-12.
13. Fry, S. A.; Van den Steen, P. E.; Royle, L.; Wormald, M. R.; Leathem, A. J.; Opdenakker, G.; McDonnell, J. M.; Dwek, R. A.; Rudd, P. M. Cancerassociated glycoforms of gelatinase B exhibit a decreased level of binding to galectin-3. Biochemistry 2006, 45, 15249-15258.
14. Gong, H. C.; Honjo, Y.; Nangia-Makker, P.; Hogan, V.; Mazurek, N.; Bresalier, R. S.; Raz, A. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res. 1999, 59, 6239-6245.
15. John, C. M.; Leffler, H.; Kahl-Knuttsson, B.; Svensson, I.; Jarvis, G. A. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin. Cancer Res. 2003, 9, 2374-2383.
16. Nangia-Makker, P.; Raz, T.; Tait, L.; Hogan, V.; Fridman, R.; Raz, A. Galectin-3 cleavage: A novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res. 2007, 67, 11760-11768.
17. Nangia-Makker, P.; Wang, Y.; Raz, T.; Tait, L.; Balan, V.; Hogan, V.; Raz, A. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int. J. Cancer 2010, 127, 2530-2541.
18. Ochieng, J.; Fridman, R.; Nangia-Makker, P.; Kleiner, D. E.; Liotta, L. A.; Stetler-Stevenson, W. G.; Raz, A. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994, 33, 14109-14114.
19. Ochieng, J.; Green, B.; Evans, S.; James, O.; Warfield, P. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim. Biophys. Acta 1998, 1379, 97-106.
20. Puthenedam, M.; Wu, F.; Shetye, A.; Michaels, A.; Rhee, K. J.; Kwon, J. H. Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells. Inflammatory Bowel Dis. 2011, 17, 260-267.
21. Saraswati, S.; Block, A. S.; Davidson, M. K.; Rank, R. G.; Mahadevan, M.; Diekman, A. B. Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate 2011, 71, 197-208.
22. Cheong, T. C.; Shin, J. Y.; Chun, K. H. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci. 2010, 101, 94-102.
23. Hoyer, K. K.; Pang, M.; Gui, D.; Shintaku, I. P.; Kuwabara, I.; Liu, F. T.; Said, J. W.; Baum, L. G.; Teitell, M. A. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am. J. Pathol. 2004, 164, 893-902.
24. Mazurek, N.; Byrd, J. C.; Sun, Y. J.; Bresalier, R. S. Galectin-3 sequence polymorphisms dictate TRAIL sensativity or resistance of human breast and colon cancer cells. Proc. Am. Assoc. Cancer Res. 2009, 50, 27.
25. Mazurek, N.; Byrd, J. C.; Sun, Y. J.; Bresalier, R. S. Nuclear galectin-3 confers tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance to colon cancer cells by inhibiting caspase-8 activation. Gastroenterology 2009, 136 (Suppl 1), A756.
26. Mazurek, N.; Byrd, J. C.; Sun, Y.; Hafley, M.; Ramirez, K.; Burks, J.; Bresalier, R. S. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 2012, 19, 523-533.
27. Mazurek, N.; Byrd, J. C.; Sun, Y.; Ueno, S.; Bresalier, R. S. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer 2011, 117, 4375-4380.
28. Meyer, A.; Coinac, I.; Bogdanova, N.; Dubrowinskaja, N.; Turmanov, N.; Haubold, S.; Schürmann, P.; Imkamp, F.; von Klot, C.; Merseburger, A. S.; Machtens, S.; Bremer, M.; Hillemanns, P.; Kuczyk, M. A.; Karstens, J. H.; Serth, J.; Dörk, T. Apoptosis gene polymorphisms and risk of prostate cancer: A hospital-based study of German patients treated with brachytherapy. Urol Oncol 2011, [Epub ahead of print] PMID:21396839.
29. Oka, N.; Nakahara, S.; Takenaka, Y.; Fukumori, T.; Hogan, V.; Kanayama, H. O.; Yanagawa, T.; Raz, A. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 2005, 65, 7546-7553.
30. Yu, F.; Finley, R. L., Jr; Raz, A.; Kim, H. R. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 2002, 277, 15819-15827.
31. Zhuo, Y.; Chammas, R.; Bellis, S. L. Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. J. Biol. Chem. 2008, 283, 22177-22185.
32. Balan, V.; Nangia-Makker, P.; Schwartz, A. G.; Jung, Y. S.; Tait, L.; Hogan, V.; Raz, T.; Wang, Y.; Yang, Z. Q.; Wu, G. S.; Guo, Y.; Li, H.; Abrams, J.; Couch, F. J.; Lingle, W. L.; Lloyd, R. V.; Ethier, S. P.; Tainsky, M. A.; Raz, A. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): A pilot study. Cancer Res. 2008, 68, 10045-10050.
33. Hu, C. Y.; Chang, S. K.; Wu, C. S.; Tsai, W. I.; Hsu, P. N. Galectin-3 gene (LGALS3) +292C allele is a genetic predisposition factor for rheumatoid arthritis in Taiwan. Clin. Rheumatol. 2011, 30, 1227-1233.
34. Martins, L.; Leoni, S.; Friguglietti, C.; Ward, L.; Kulcsar, M.; Kimura, E. Polymorphism on codon 98 of the galectin-3 gene are not associated to benign and malignant thyroid tumors. Arq. Bras. Endocrinol. Metab. 2006, 50, 1075-1081.
35. Poirier, O.; Nicaud, V.; Vionnet, N.; Raoux, S.; Tarnow, L.; Vlassara, H.; Parving, H.; Cambien, F. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors association study with nephropathy in type 1 diabetic patients. Diabetes 2001, 50, 1214-1218.
36. Schoeppner, H. L.; Raz, A.; Ho, S. B.; Bresalier, R. S. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75, 2818-2826.
37. Irimura, T.; Matsushita, Y.; Sutton, R. C.; Carralero, D.; Ohannesian, D. W.; Cleary, K. R.; Ota, D. M.; Nicolson, G. L.; Lotan, R. Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res. 1991, 51, 387-393.
38. Hittelet, A.; Legendre, H.; Nagy, N.; Bronckart, Y.; Pector, J. C.; Salmon, I.; Yeaton, P.; Gabius, H. J.; Kiss, R.; Camby, I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer 2003, 103, 370-379.
39. Inufusa, H.; Nakamura, M.; Adachi, T.; Aga, M.; Kurimoto, M.; Nakatani, Y.; Wakano, T.; Miyake, M.; Okuno, K.; Shiozaki, H.; Yasutomi, M. Role of galectin-3 in adenocarcinoma liver metastasis. Int. J. Oncol. 2001, 19, 913-919.
40. Iurisci, I.; Tinari, N.; Natoli, C.; Angelucci, D.; Cianchetti, E.; Iacobelli, S. Concentration of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 2000, 6, 1389-1393.
41. Bresalier, R. S.; Byrd, J. C.; Tessler, D.; Lebel, J.; Koomen, J.; Hawke, D.; Half, E.; Liu, K. F.; Mazurek, N.; Mazurek, N. A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology 2004, 127, 741-748.
42. Hausdek, K. C.; Spronnk, K. J.; Voss, P. G.; Patterson, R. J.; Wang, J. L.; Arnoys, E. J. Dynamics ofgalectin-3 in the nucleus and cytoplasm. Biochim. Biophys. Acta 2010, 1800, 181-189.
43. Kim, S. J.; Choi, I. J.; Cheong, T. C.; Lee, S. J.; Lotan, R.; Park, S. H.; Chun, K. H. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010, 138, 1035-1045.
44. Song, S.; Byrd, J. C.; Mazurek, N.; Liu, K.; Koo, J. S.; Bresalier, R. S. Galectin-3 modulates MUC2 mucin expression in human colon cancer cells at the level of transcription via AP-1 activation. Gastroenterology 2005, 129, 1581-1591.
45. Bresalier, R. S.; Byrd, J. C.; Wang, L.; Raz, A. Colon cancer mucin: A new ligand for the beta-galactoside binding protein galectin-3. Cancer Res. 1996, 56, 4354-4357.
46. Thiemann, S.; Baum, L. G. The road less traveled: Regulation of leukocyte migration across vascular and lymphatic endothelium by galectins. J. Clin. Immunol. 2011, 3, 2-9.
47. Nangia-Makker, P.; Balan, V.; Raz, A Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron. 2008, 1, 43-51.
48. Wei, J.; Barr, J.; Kong, L. Y.; Wang, Y.; Wu, A.; Sharma, A. K.; Gumin, J.; Henry, V.; Colman, H.; Sawaya, R.; Lang, F. F.; Heimberger, A. B. Gliomaassociated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 2010, 16, 461-473.
49. Filer, A.; Bik, M.; Parsonage, G. N.; Fitton, J.; Trebilcock, E.; Howlett, K.; Cook, M.; Raza, K.; Simmons, D. L.; Thomas, A. M.; Salmon, M.; Scheel-Toellner, D.; Lord, J. M.; Rabinovich, G. A.; Buckley, C. D. Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. Arthritis Rheum. 2009, 60, 1604-1614.
50. Al-Awqati, Q Terminal differentiation in epithelia: The role of integrins in hensin polymerization. Annu. Rev. Physiol. 2011, 73, 401-412.
51. Merlin, J.; Stechly, L.; de Beaucé, S.; Monté, D.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011, 30, 2514-2525.
52. Markowska, A. I.; Liu, F. T.; Panjwani, N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 2010, 207, 1981-1993.
53. Guo, H. B.; Johnson, H.; Randolph, M.; Lee, I.; Pierce, M. Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. Glycobiology 2009, 19, 547-559.
54. Shalom-Feuerstein, R.; Plowman, S. J.; Rotblat, B.; Ariotti, N.; Tian, T.; Hancock, J. F.; Kloog, Y. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res. 2008, 68, 6608-6616.
55. Dermotte, N.; Wieers, G.; Van Der Smissen, P.; Moser, M.; Schmidt, C.; Thielemans, K.; Squifflet, J. L.; Weynand, B.; Carrasco, J.; Lurquin, C.; Courtoy, P. J.; van der Bruggen, P. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010, 70, 7476-7488.
56. Song, S.; Mazurek, N.; Liu, C.; Sun, Y.; Ding, Q. Q.; Liu, K.; Hung, M. C.; Bresalier, R. S. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009, 69, 1343-1349.
57. Shimura, T; Takenaka, Y.; Fukumori, T.; Tsutsumi, S.; Okada, K.; Hogan, V.; Kikuchi, A.; Kuwano, H.; Raz, A. Implication of galectin-3 in Wnt signaling. Cancer Res. 2005, 65, 3535-3537.
58. Choi, J. H.; Chun, K. H.; Raz, A.; Lotan, R. Inhibition of N-(4- hydroxyphenyl)retinamide-induced apoptosis in breast cancer cells by galectin-3. Cancer Biol. Ther. 2004, 3, 447-452.
59. Akahani, S.; Nangia-Makker, P.; Inohara, H.; Kim, H. R.; Raz, A. Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997, 57, 5272-5276.
60. Cretney, E.; Takeda, K.; Smytha, M. J. Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int. J. Biochem. Cell Biol. 2007, 39, 280-286.
61. Cretney, E.; Takeda, K.; Yagita, H.; Glaccum, M.; Peschon, J. J.; Smyth, M. J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 2002, 168, 1356-1361.
62. Takeda, K.; Hayakawa, Y.; Smyth, M. J.; Kayagaki, N.; Yamaguchi, N.; Kakuta, S.; Iwakura, Y.; Yagita, H.; Okumura, K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 2001, 7, 94-100.
63. Aza-Blanc, P.; Cooper, C. L.; Wagner, K.; Batalov, S.; Deveraux, Q. L.; Cooke, M. P. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell. 2003, 12, 627-637.
64. Kendrick, J. E.; Estes, J. M.; Straughn, J. M.; Alvarez, R. D.; Buchsbaum, D. J. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol. Oncol. 2007, 106, 614-621.
65. Laiyemo, A. O.; Doubeni, C.; Pinsky, P. F.; Doria-Rose, V. P.; Bresalier, R.; Lamerato, L. E.; Crawford, E. D.; Kvale, P.; Fouad, M.; Hickey, T.; Riley, T.; Weissfeld, J.; Schoen, R. E.; Marcus, P. M.; Prorok, P. C.; Berg, C. D. Race and colorectal cancer disparities: Health-care utilization vs different cancer susceptibilities. J. Natl. Cancer Inst. 2010, 102, 538-546.
66. Dhirapong, A.; Lleo, A.; Leung, P.; Gershwin, M. E.; Liu, F. T. The immunological potential of galectin-1 and -3. Autoimmun. Rev. 2009, 8, 360-363.
67. Dumic, J.; Dabelic, S.; Flögel, M. Galectin-3: An open-ended story. Biochim. Biophys. Acta 2006, 1760, 616-635.
68. Fukumori, T.; Kanayama, H. O.; Raz, A. The role of galectin-3 in cancer drug resistance. Drug Resist. Updates 2007, 10, 101-108.